JP2023531252A5 - - Google Patents

Info

Publication number
JP2023531252A5
JP2023531252A5 JP2022580096A JP2022580096A JP2023531252A5 JP 2023531252 A5 JP2023531252 A5 JP 2023531252A5 JP 2022580096 A JP2022580096 A JP 2022580096A JP 2022580096 A JP2022580096 A JP 2022580096A JP 2023531252 A5 JP2023531252 A5 JP 2023531252A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cancer
chain containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580096A
Other languages
English (en)
Japanese (ja)
Other versions
JP7798811B2 (ja
JP2023531252A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000445 external-priority patent/WO2021260438A1/en
Publication of JP2023531252A publication Critical patent/JP2023531252A/ja
Publication of JP2023531252A5 publication Critical patent/JP2023531252A5/ja
Priority to JP2025283168A priority Critical patent/JP2026053657A/ja
Application granted granted Critical
Publication of JP7798811B2 publication Critical patent/JP7798811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022580096A 2020-06-26 2021-06-25 抗b7-h3抗体を含む抗体-薬物コンジュゲート Active JP7798811B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025283168A JP2026053657A (ja) 2020-06-26 2025-12-25 抗b7-h3抗体を含む抗体-薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044764P 2020-06-26 2020-06-26
US63/044,764 2020-06-26
PCT/IB2021/000445 WO2021260438A1 (en) 2020-06-26 2021-06-25 Antibody-drug conjugates comprising anti-b7-h3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025283168A Division JP2026053657A (ja) 2020-06-26 2025-12-25 抗b7-h3抗体を含む抗体-薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2023531252A JP2023531252A (ja) 2023-07-21
JP2023531252A5 true JP2023531252A5 (cg-RX-API-DMAC7.html) 2024-07-02
JP7798811B2 JP7798811B2 (ja) 2026-01-14

Family

ID=79282029

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580096A Active JP7798811B2 (ja) 2020-06-26 2021-06-25 抗b7-h3抗体を含む抗体-薬物コンジュゲート
JP2025283168A Pending JP2026053657A (ja) 2020-06-26 2025-12-25 抗b7-h3抗体を含む抗体-薬物コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025283168A Pending JP2026053657A (ja) 2020-06-26 2025-12-25 抗b7-h3抗体を含む抗体-薬物コンジュゲート

Country Status (11)

Country Link
US (2) US12168060B2 (cg-RX-API-DMAC7.html)
EP (1) EP4171655A4 (cg-RX-API-DMAC7.html)
JP (2) JP7798811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230028793A (cg-RX-API-DMAC7.html)
CN (2) CN115942978A (cg-RX-API-DMAC7.html)
AU (1) AU2021297036A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026401A2 (cg-RX-API-DMAC7.html)
CA (1) CA3182602A1 (cg-RX-API-DMAC7.html)
IL (1) IL299362A (cg-RX-API-DMAC7.html)
MX (1) MX2022016180A (cg-RX-API-DMAC7.html)
WO (1) WO2021260438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112166115A (zh) 2018-05-29 2021-01-01 尹图赛利有限公司 新型苯二氮杂*衍生物及其用途
EP3873912B1 (en) 2018-10-31 2026-03-25 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
CN114728075B (zh) * 2019-12-02 2025-10-03 尹图赛利有限公司 与分子缀合相关的组合物和方法
CN115942978A (zh) 2020-06-26 2023-04-07 尹图赛利有限公司 包含抗b7-h3抗体的抗体-药物缀合物
MX2024008036A (es) * 2021-12-28 2024-07-15 Beigene Switzerland Gmbh Conjugados de anticuerpo y farmaco.
AU2022446336A1 (en) * 2022-03-18 2024-09-19 Beijing Mabworks Biotech Co., Ltd B7-h3-binding antibody and use thereof
CN120417939A (zh) * 2022-10-28 2025-08-01 伊莱利利公司 用于生物缀合的自水解马来酰亚胺
TW202438527A (zh) * 2023-03-17 2024-10-01 瑞士商百濟神州瑞士有限責任公司 抗b7h3抗體以及其使用方法
WO2024225838A1 (ko) * 2023-04-28 2024-10-31 주식회사 에이비켐바이오 균일한 dar을 갖는 말레이미드 함유 링커를 포함하는 항체-약물 중합체의 제조방법
CN120957756A (zh) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和用途
CN116949044B (zh) * 2023-09-20 2023-12-12 北京炫景瑞医药科技有限公司 一种双链寡链核苷酸、包含该双链寡核苷酸的缀合物以及它们的用途
CN117717536A (zh) * 2023-11-03 2024-03-19 吉林农业大学 一种玉米醇溶蛋白胶囊的制备工艺
CN117777296B (zh) * 2024-02-28 2024-05-28 北京肿瘤医院(北京大学肿瘤医院) B7h3亲和体及其诊疗核素标记物的制备方法与应用
WO2025237246A1 (en) * 2024-05-11 2025-11-20 Westlake Laboratory Of Life Sciences And Biomedicine Novel covalent protein and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6613304B2 (ja) 2014-09-17 2019-12-04 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗cd276抗体(b7h3)
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
RS61828B1 (sr) * 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
CA3056474A1 (en) * 2017-03-31 2018-10-04 Jiangsu Hengrui Medicine Co., Ltd. B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
KR102710962B1 (ko) * 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
CN112166115A (zh) * 2018-05-29 2021-01-01 尹图赛利有限公司 新型苯二氮杂*衍生物及其用途
EP3873912B1 (en) * 2018-10-31 2026-03-25 Intocell, Inc. Fused heterocyclic benzodiazepine derivatives and uses thereof
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN115942978A (zh) 2020-06-26 2023-04-07 尹图赛利有限公司 包含抗b7-h3抗体的抗体-药物缀合物

Similar Documents

Publication Publication Date Title
JP2021523232A5 (cg-RX-API-DMAC7.html)
TWI847992B (zh) 抗體-藥物結合物之有效的製造方法
CN113710277B (zh) 一种负载双毒素的抗体药物偶联物及其应用
JP2021063058A5 (cg-RX-API-DMAC7.html)
JP2025041725A5 (cg-RX-API-DMAC7.html)
JP2021516976A5 (cg-RX-API-DMAC7.html)
JP2022522547A5 (cg-RX-API-DMAC7.html)
JP2021516975A5 (cg-RX-API-DMAC7.html)
JP7769032B2 (ja) 抗体-薬物コンジュゲート投与による転移性脳腫瘍の治療
JP2010538972A (ja) 転移性癌の処置のためのvegfr−2阻害剤の使用
JP2021519076A (ja) ヒト化抗前立腺特異的膜抗原(psma)抗体薬物複合体
EA038192B1 (ru) Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение
CN115052632B (zh) 靶向多肽-药物缀合物及其用途
JP2020522281A5 (cg-RX-API-DMAC7.html)
TWI807320B (zh) 含有α-烯醇酶抗體之藥物共軛物及其用途
CN120826405A (zh) 具有靶向作用的偶联物及其制备方法和用途
TW201713365A (zh) 遞送治療藥物之ph-敏感性的連接物
JP2020533965A5 (cg-RX-API-DMAC7.html)
EP3906064A1 (en) Compounds comprising cleavable linker and uses thereof
KR20250075746A (ko) 항체 및 이의 제조 및 사용 방법
KR20250156815A (ko) 인간 l1cam에 대한 항체를 포함하는 항체-약물 접합체 및 이의 용도
TW202546007A (zh) 抗體藥物結合物
AU2024236246A1 (en) Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor
JP2025511705A5 (cg-RX-API-DMAC7.html)
JP2024542879A5 (cg-RX-API-DMAC7.html)